argenx to Acquire Forte Biosciences, Inc.

Neurocrine Biosciences to Acquire Celeno Therapeutics

April 7, 2026

Healthcare Services

Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Bruker Corporation to Acquire PhenomeX Inc for $108 Million

August 17, 2023

Medical Devices

Bruker Corporation has signed a definitive agreement to acquire PhenomeX Inc in an all-cash transaction valued at approximately $108 million equity value ($1.00 per share). The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions, after which PhenomeX will merge into a wholly owned Bruker subsidiary.

Aceragen Acquires Arrevus to Expand Late-Stage Rare Disease Pipeline

October 28, 2021

Biotechnology

Aceragen, Inc. acquired clinical-stage biopharmaceutical company Arrevus, Inc., adding Arrevus' lead oral anti-infective candidate ARV-1801 (renamed ACG-721) and several preclinical programs to Aceragen's rare-disease pipeline. The deal brings additional clinical and regulatory capabilities to Aceragen and is expected to be accretive as the company advances registrational and Phase 2/3 studies in cystic fibrosis and other orphan indications.

Abenex Acquires Cisbio Bioassays from Argos Soditic

June 16, 2016

Biotechnology

French private equity firm Abenex has acquired Cisbio Bioassays from seller Argos Soditic. Abenex will partner with the biotech to support its organic and external growth strategy across pharmaceutical research and in vitro diagnostics; Cisbio has ~210 employees and generates over 85% of revenue outside France.